155 related articles for article (PubMed ID: 26267318)
1. DNA repair prognostic index modelling reveals an essential role for base excision repair in influencing clinical outcomes in ER negative and triple negative breast cancers.
Abdel-Fatah TM; Arora A; Moseley PM; Perry C; Rakha EA; Green AR; Chan SY; Ellis IO; Madhusudan S
Oncotarget; 2015 Sep; 6(26):21964-78. PubMed ID: 26267318
[TBL] [Abstract][Full Text] [Related]
2. Is there a role for base excision repair in estrogen/estrogen receptor-driven breast cancers?
Abdel-Fatah TM; Perry C; Arora A; Thompson N; Doherty R; Moseley PM; Green AR; Chan SY; Ellis IO; Madhusudan S
Antioxid Redox Signal; 2014 Dec; 21(16):2262-8. PubMed ID: 25111287
[TBL] [Abstract][Full Text] [Related]
3. Clinicopathological significance of human apurinic/apyrimidinic endonuclease 1 (APE1) expression in oestrogen-receptor-positive breast cancer.
Abdel-Fatah TM; Perry C; Moseley P; Johnson K; Arora A; Chan S; Ellis IO; Madhusudan S
Breast Cancer Res Treat; 2014 Feb; 143(3):411-21. PubMed ID: 24381055
[TBL] [Abstract][Full Text] [Related]
4. BRCAness as a Biomarker for Predicting Prognosis and Response to Anthracycline-Based Adjuvant Chemotherapy for Patients with Triple-Negative Breast Cancer.
Mori H; Kubo M; Nishimura R; Osako T; Arima N; Okumura Y; Okido M; Yamada M; Kai M; Kishimoto J; Miyazaki T; Oda Y; Otsuka T; Nakamura M
PLoS One; 2016; 11(12):e0167016. PubMed ID: 27977696
[TBL] [Abstract][Full Text] [Related]
5. Pathological complete response after cisplatin neoadjuvant therapy is associated with the downregulation of DNA repair genes in BRCA1-associated triple-negative breast cancers.
Domagala P; Hybiak J; Rys J; Byrski T; Cybulski C; Lubinski J
Oncotarget; 2016 Oct; 7(42):68662-68673. PubMed ID: 27626685
[TBL] [Abstract][Full Text] [Related]
6. Biological and clinical significance of PARP1 protein expression in breast cancer.
Green AR; Caracappa D; Benhasouna AA; Alshareeda A; Nolan CC; Macmillan RD; Madhusudan S; Ellis IO; Rakha EA
Breast Cancer Res Treat; 2015 Jan; 149(2):353-62. PubMed ID: 25528020
[TBL] [Abstract][Full Text] [Related]
7. Germline mutations in DNA repair genes may predict neoadjuvant therapy response in triple negative breast patients.
Spugnesi L; Gabriele M; Scarpitta R; Tancredi M; Maresca L; Gambino G; Collavoli A; Aretini P; Bertolini I; Salvadori B; Landucci E; Fontana A; Rossetti E; Roncella M; Naccarato GA; Caligo MA
Genes Chromosomes Cancer; 2016 Dec; 55(12):915-924. PubMed ID: 27328445
[TBL] [Abstract][Full Text] [Related]
8. Targeting BRCA1-BER deficient breast cancer by ATM or DNA-PKcs blockade either alone or in combination with cisplatin for personalized therapy.
Albarakati N; Abdel-Fatah TM; Doherty R; Russell R; Agarwal D; Moseley P; Perry C; Arora A; Alsubhi N; Seedhouse C; Rakha EA; Green A; Ball G; Chan S; Caldas C; Ellis IO; Madhusudan S
Mol Oncol; 2015 Jan; 9(1):204-17. PubMed ID: 25205036
[TBL] [Abstract][Full Text] [Related]
9. A CLDN1-negative phenotype predicts poor prognosis in triple-negative breast cancer.
Ma F; Ding X; Fan Y; Ying J; Zheng S; Lu N; Xu B
PLoS One; 2014; 9(11):e112765. PubMed ID: 25393310
[TBL] [Abstract][Full Text] [Related]
10. Clinical Impact of Tumor DNA Repair Expression and T-cell Infiltration in Breast Cancers.
Green AR; Aleskandarany MA; Ali R; Hodgson EG; Atabani S; De Souza K; Rakha EA; Ellis IO; Madhusudan S
Cancer Immunol Res; 2017 Apr; 5(4):292-299. PubMed ID: 28254786
[TBL] [Abstract][Full Text] [Related]
11. Coexistent Loss of the Expressions of BRCA1 and p53 Predicts Poor Prognosis in Triple-Negative Breast Cancer.
Kim MC; Choi JE; Lee SJ; Bae YK
Ann Surg Oncol; 2016 Oct; 23(11):3524-3530. PubMed ID: 27278204
[TBL] [Abstract][Full Text] [Related]
12. BRCA1 promoter methylation is a marker of better response to anthracycline-based therapy in sporadic TNBC.
Ignatov T; Poehlmann A; Ignatov A; Schinlauer A; Costa SD; Roessner A; Kalinski T; Bischoff J
Breast Cancer Res Treat; 2013 Sep; 141(2):205-12. PubMed ID: 24026861
[TBL] [Abstract][Full Text] [Related]
13. Increased ID4 expression, accompanied by mutant p53 accumulation and loss of BRCA1/2 proteins in triple-negative breast cancer, adversely affects survival.
Thike AA; Tan PH; Ikeda M; Iqbal J
Histopathology; 2016 Apr; 68(5):702-12. PubMed ID: 26259780
[TBL] [Abstract][Full Text] [Related]
14. Clinicopathological significance of ATM-Chk2 expression in sporadic breast cancers: a comprehensive analysis in large cohorts.
Abdel-Fatah TM; Arora A; Alsubhi N; Agarwal D; Moseley PM; Perry C; Doherty R; Chan SY; Green AR; Rakha E; Ball G; Ellis IO; Madhusudan S
Neoplasia; 2014 Nov; 16(11):982-91. PubMed ID: 25425972
[TBL] [Abstract][Full Text] [Related]
15. Nottingham Clinico-Pathological Response Index (NPRI) after neoadjuvant chemotherapy (Neo-ACT) accurately predicts clinical outcome in locally advanced breast cancer.
Abdel-Fatah TM; Ball G; Lee AH; Pinder S; MacMilan RD; Cornford E; Moseley PM; Silverman R; Price J; Latham B; Palmer D; Chan A; Ellis IO; Chan SY
Clin Cancer Res; 2015 Mar; 21(5):1052-62. PubMed ID: 25520390
[TBL] [Abstract][Full Text] [Related]
16. Single-strand selective monofunctional uracil-DNA glycosylase (SMUG1) deficiency is linked to aggressive breast cancer and predicts response to adjuvant therapy.
Abdel-Fatah TM; Albarakati N; Bowell L; Agarwal D; Moseley P; Hawkes C; Ball G; Chan S; Ellis IO; Madhusudan S
Breast Cancer Res Treat; 2013 Dec; 142(3):515-27. PubMed ID: 24253812
[TBL] [Abstract][Full Text] [Related]
17. Hypermethylation of BRCA1 gene: implication for prognostic biomarker and therapeutic target in sporadic primary triple-negative breast cancer.
Zhu X; Shan L; Wang F; Wang J; Wang F; Shen G; Liu X; Wang B; Yuan Y; Ying J; Yang H
Breast Cancer Res Treat; 2015 Apr; 150(3):479-86. PubMed ID: 25783183
[TBL] [Abstract][Full Text] [Related]
18. Prognostic significance of tumor-infiltrating CD8+ and FOXP3+ lymphocytes in residual tumors and alterations in these parameters after neoadjuvant chemotherapy in triple-negative breast cancer: a retrospective multicenter study.
Miyashita M; Sasano H; Tamaki K; Hirakawa H; Takahashi Y; Nakagawa S; Watanabe G; Tada H; Suzuki A; Ohuchi N; Ishida T
Breast Cancer Res; 2015 Sep; 17(1):124. PubMed ID: 26341640
[TBL] [Abstract][Full Text] [Related]
19. BRCA1-IRIS inactivation overcomes paclitaxel resistance in triple negative breast cancers.
Blanchard Z; Paul BT; Craft B; ElShamy WM
Breast Cancer Res; 2015 Jan; 17(1):5. PubMed ID: 25583261
[TBL] [Abstract][Full Text] [Related]
20. New insights into the prognostic value of Ki-67 labeling index in patients with triple-negative breast cancer.
Hao S; He ZX; Yu KD; Yang WT; Shao ZM
Oncotarget; 2016 Apr; 7(17):24824-31. PubMed ID: 27050075
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
